https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3b-exploratory-multicenter-open-label-study-to-evaluate-the-effect-of-bimekizumab-on-gene-expression-biomarkers-in-study-participants-with-moderate-to-severe-plaque-psoriasis-r19/ 2026-03-08T01:00:00+01:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-multicenter-randomized-double-blind-placebo-controlled-phase-3-study-to-evaluate-the-efficacy-safety-and-pharmacokinetics-of-deucravacitinib-in-adolescent-subjects-12-years-to-less-than-18-years-with-moderate-to-severe-plaque-psoriasis-r18/ 2026-03-06T01:00:00+01:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-iii-randomized-double-blind-placebo-controlled-study-to-demonstrate-the-efficacy-and-safety-of-tildrakizumab-in-anti-tnf-experienced-subjects-with-active-psoriatic-arthritis-i-inspire-1-r17/ 2026-02-24T01:00:00+01:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/molecular-inflammation-board-at-the-center-for-personalized-medicine-r15/ 2025-08-20T06:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/long-term-safety-study-of-deucravacitinib-versus-ustekinumab-in-participants-with-psoriasis-pragmatyk-r16/ 2025-08-14T06:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3-parallel-group-randomized-double-blind-3-arm-placebo-controlled-multicenter-study-to-investigate-the-efficacy-and-safety-of-subcutaneous-sonelokimab-in-male-and-female-participants-aged-18-years-and-over-with-active-psoriatic-arthritis-who-are-n-r1/ 2025-05-31T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3-parallel-group-randomized-double-blind-4-arm-placebo-controlled-multicenter-study-with-risankizumab-as-active-reference-arm-to-investigate-the-efficacy-and-safety-of-subcutaneous-sonelokimab-in-male-and-female-participants-aged-18-years-and-over-r2/ 2025-05-31T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-multicenter-randomized-double-blind-placebo-and-active-comparator-controlled-phase-3-study-to-evaluate-the-efficacy-and-safety-of-esk-001-in-patients-with-moderate-to-severe-plaque-psoriasis-onward1-r3/ 2025-05-31T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-study-to-evaluate-the-efficacy-safety-and-drug-levels-of-deucravacitinib-bms-986165-in-adolescent-participants-with-moderate-to-severe-plaque-psoriasis-r6/ 2025-05-29T06:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/an-open-label-multi-center-extension-study-to-characterize-the-long-term-safety-and-efficacy-of-bms-986165-in-subjects-with-moderate-to-severe-plaque-psoriasis-r4/ 2025-05-28T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/22104-a-randomized-double-blind-placebo-controlled-multicenter-phase-2b3-study-to-evaluate-the-efficacy-and-safety-of-izokibep-in-subjects-with-active-psoriatic-arthritis-r5/ 2025-05-28T02:00:00+02:00 1